Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Spira

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|December 8, 2022
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical ApplicationsByoung Chul Cho, Allison Simi, Joshua Sabari, et al.
Human Vaccines & Immunotherapeutics|December 2, 2017
Product review on the Anti-PD-L1 antibody atezolizumabNeil J Shah, William J Kelly, Stephen V Liu, et al.
Oncotargets and Therapy|December 2, 2021
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion DiagnosticsMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Cancer Treatment and Research Communications|June 10, 2023
Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancerMayur M Amonkar, Monica Chase, Nicole M Myer, et al.
Journal of Health Economics and Outcomes Research|May 22, 2026
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus ChemotherapyAlexander Spira, Pratyusha Vadagam, Iris Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2023
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyondJhanelle E Gray, Hil Hsu, Diana Younan, et al.
Clinical Lung Cancer|August 9, 2018
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment FailureDavid A Barbie, Alexander Spira, Karen Kelly, et al.
Future Oncology (London, England)|August 17, 2023
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Cancer Treatment and Research Communications|May 23, 2025
Real-world treatment patterns of patients with EGFR exon 20 insertion-mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort studyAlexander Spira, Dexter Waters, Tao Ran, et al.
Lung Cancer (Amsterdam, Netherlands)|October 6, 2024
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)Melissa Johnson, Diana Younan, Shia T Kent, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|December 8, 2022
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical ApplicationsByoung Chul Cho, Allison Simi, Joshua Sabari, et al.
Human Vaccines & Immunotherapeutics|December 2, 2017
Product review on the Anti-PD-L1 antibody atezolizumabNeil J Shah, William J Kelly, Stephen V Liu, et al.
Oncotargets and Therapy|December 2, 2021
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion DiagnosticsMatthew Z Guo, Kristen A Marrone, Alexander Spira, et al.
Cancer Treatment and Research Communications|June 10, 2023
Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancerMayur M Amonkar, Monica Chase, Nicole M Myer, et al.
Journal of Health Economics and Outcomes Research|May 22, 2026
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus ChemotherapyAlexander Spira, Pratyusha Vadagam, Iris Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|June 7, 2023
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyondJhanelle E Gray, Hil Hsu, Diana Younan, et al.
Clinical Lung Cancer|August 9, 2018
Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment FailureDavid A Barbie, Alexander Spira, Karen Kelly, et al.
Future Oncology (London, England)|August 17, 2023
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Cancer Treatment and Research Communications|May 23, 2025
Real-world treatment patterns of patients with EGFR exon 20 insertion-mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort studyAlexander Spira, Dexter Waters, Tao Ran, et al.
Lung Cancer (Amsterdam, Netherlands)|October 6, 2024
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)Melissa Johnson, Diana Younan, Shia T Kent, et al.
Pageof 9